Logo image of TNG.PA

TRANSGENE SA (TNG.PA) Stock Fundamental Analysis

Europe - EPA:TNG - FR0005175080 - Common Stock

1.363 EUR
+0.02 (+1.34%)
Last: 10/24/2025, 10:05:08 AM
Fundamental Rating

1

TNG gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 76 industry peers in the Biotechnology industry. TNG has a bad profitability rating. Also its financial health evaluation is rather negative. TNG is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

TNG had negative earnings in the past year.
In the past year TNG has reported a negative cash flow from operations.
In the past 5 years TNG always reported negative net income.
TNG had a negative operating cash flow in each of the past 5 years.
TNG.PA Yearly Net Income VS EBIT VS OCF VS FCFTNG.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M -40M

1.2 Ratios

TNG has a worse Return On Assets (-82.88%) than 69.74% of its industry peers.
Industry RankSector Rank
ROA -82.88%
ROE N/A
ROIC N/A
ROA(3y)-59.77%
ROA(5y)-43.73%
ROE(3y)-151.05%
ROE(5y)-103.3%
ROIC(3y)N/A
ROIC(5y)N/A
TNG.PA Yearly ROA, ROE, ROICTNG.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150 -200

1.3 Margins

TNG does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TNG.PA Yearly Profit, Operating, Gross MarginsTNG.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400

More info and screens

0

2. Health

2.1 Basic Checks

TNG does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for TNG has been increased compared to 1 year ago.
The number of shares outstanding for TNG has been increased compared to 5 years ago.
The debt/assets ratio for TNG has been reduced compared to a year ago.
TNG.PA Yearly Shares OutstandingTNG.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
TNG.PA Yearly Total Debt VS Total AssetsTNG.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

TNG has an Altman-Z score of -2.85. This is a bad value and indicates that TNG is not financially healthy and even has some risk of bankruptcy.
TNG has a worse Altman-Z score (-2.85) than 65.79% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -2.85
ROIC/WACCN/A
WACC7.83%
TNG.PA Yearly LT Debt VS Equity VS FCFTNG.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M 60M

2.3 Liquidity

TNG has a Current Ratio of 0.54. This is a bad value and indicates that TNG is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 0.54, TNG is doing worse than 84.21% of the companies in the same industry.
A Quick Ratio of 0.54 indicates that TNG may have some problems paying its short term obligations.
With a Quick ratio value of 0.54, TNG is not doing good in the industry: 82.89% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.54
Quick Ratio 0.54
TNG.PA Yearly Current Assets VS Current LiabilitesTNG.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

3

3. Growth

3.1 Past

TNG shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -31.17%.
The Revenue for TNG has decreased by -20.34% in the past year. This is quite bad
Measured over the past years, TNG shows a very negative growth in Revenue. The Revenue has been decreasing by -14.48% on average per year.
EPS 1Y (TTM)-31.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%10.84%
Revenue 1Y (TTM)-20.34%
Revenue growth 3Y-29.03%
Revenue growth 5Y-14.48%
Sales Q2Q%36.11%

3.2 Future

TNG is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -1.72% yearly.
TNG is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 29.98% yearly.
EPS Next Y125.93%
EPS Next 2Y-13.04%
EPS Next 3Y-16.33%
EPS Next 5Y-1.72%
Revenue Next Year-31.56%
Revenue Next 2Y-2.11%
Revenue Next 3Y9.15%
Revenue Next 5Y29.98%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
TNG.PA Yearly Revenue VS EstimatesTNG.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 10M 20M 30M 40M 50M
TNG.PA Yearly EPS VS EstimatesTNG.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -0.2 -0.4 -0.6 -0.8 -1

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

TNG reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TNG. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TNG.PA Price Earnings VS Forward Price EarningsTNG.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TNG.PA Per share dataTNG.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.1 -0.2 -0.3

4.3 Compensation for Growth

TNG's earnings are expected to decrease with -16.33% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-13.04%
EPS Next 3Y-16.33%

More info and screens

0

5. Dividend

5.1 Amount

TNG does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TRANSGENE SA

EPA:TNG (10/24/2025, 10:05:08 AM)

1.363

+0.02 (+1.34%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)09-16 2025-09-16
Earnings (Next)11-04 2025-11-04
Inst Owners0.68%
Inst Owner ChangeN/A
Ins Owners0.69%
Ins Owner ChangeN/A
Market Cap180.92M
Revenue(TTM)6.08M
Net Income(TTM)-33971000
Analysts82.86
Price Target1.8 (32.06%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)3.92%
PT rev (3m)3.92%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)27.27%
EPS NY rev (3m)27.27%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-14.29%
Revenue NY rev (3m)-36.51%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 29.75
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.29
EYN/A
EPS(NY)-0.35
Fwd EYN/A
FCF(TTM)-0.18
FCFYN/A
OCF(TTM)-0.17
OCFYN/A
SpS0.05
BVpS-0.03
TBVpS-0.03
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -82.88%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-59.77%
ROA(5y)-43.73%
ROE(3y)-151.05%
ROE(5y)-103.3%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.15
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 100.08%
Cap/Sales 22.05%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.54
Quick Ratio 0.54
Altman-Z -2.85
F-Score2
WACC7.83%
ROIC/WACCN/A
Cap/Depr(3y)165.93%
Cap/Depr(5y)113.96%
Cap/Sales(3y)33.44%
Cap/Sales(5y)22.59%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-31.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%10.84%
EPS Next Y125.93%
EPS Next 2Y-13.04%
EPS Next 3Y-16.33%
EPS Next 5Y-1.72%
Revenue 1Y (TTM)-20.34%
Revenue growth 3Y-29.03%
Revenue growth 5Y-14.48%
Sales Q2Q%36.11%
Revenue Next Year-31.56%
Revenue Next 2Y-2.11%
Revenue Next 3Y9.15%
Revenue Next 5Y29.98%
EBIT growth 1Y-18.8%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year130.19%
EBIT Next 3Y-19.33%
EBIT Next 5YN/A
FCF growth 1Y30.68%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y29.37%
OCF growth 3YN/A
OCF growth 5YN/A